Clal Biotechnology Industries Ltd Market Cap ($9.63 Million)
Market Cap & Net Worth: Clal Biotechnology Industries Ltd (CBI)
Clal Biotechnology Industries Ltd market cap. Clal Biotechnology Industries Ltd (TA:CBI) has a market capitalization of $9.63 Million (ILA3.59 Billion) as of November 1, 2026. Listed on the TA stock exchange, this Israel-based company holds position #27037 globally and #382 in its home market, demonstrating a -2.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Clal Biotechnology Industries Ltd's stock price ILA22.90 by its total outstanding shares 156846200 (156.85 Million). Also see Clal Biotechnology Industries Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Clal Biotechnology Industries Ltd Market Cap History (2015–2026)
Clal Biotechnology Industries Ltd market cap history from 2015 to 2026. Data shows change from $121.28 Million to $9.63 Million (-19.31% CAGR). Check Clal Biotechnology Industries Ltd share price for real-time trading data and today's change.
Clal Biotechnology Industries Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Clal Biotechnology Industries Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore CBI year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
33.70x
Clal Biotechnology Industries Ltd's market cap is 33.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $121.28 Million | $25.42 Million | -$118.46 Million | 4.77x | N/A |
| 2016 | $89.59 Million | $24.18 Million | -$213.82 Million | 3.70x | N/A |
| 2017 | $125.68 Million | $43.46 Million | -$27.89 Million | 2.89x | N/A |
| 2018 | $101.90 Million | $12.77 Million | -$44.94 Million | 7.98x | N/A |
| 2019 | $49.20 Million | $113.29 Million | -$154.11 Million | 0.43x | N/A |
| 2020 | $73.83 Million | $206.00K | $109.03 Million | 358.41x | 0.68x |
| 2021 | $49.70 Million | $224.00K | -$89.58 Million | 221.89x | N/A |
| 2022 | $26.79 Million | $370.00K | -$61.74 Million | 72.39x | N/A |
| 2023 | $16.65 Million | $104.00K | -$31.05 Million | 160.11x | N/A |
| 2024 | $14.59 Million | $433.00K | -$62.46 Million | 33.70x | N/A |
Competitor Companies of CBI by Market Capitalization
Companies near Clal Biotechnology Industries Ltd in the global market cap rankings as of November 1, 2026. Also see Clal Biotechnology Industries Ltd (CBI) total assets for a full breakdown of the balance sheet.
Key companies related to Clal Biotechnology Industries Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Clal Biotechnology Industries Ltd (2015–2026)
Market capitalization of Clal Biotechnology Industries Ltd from 2015 to today. Between 2015 and today, Clal Biotechnology Industries Ltd's market cap moved from $121.28 Million to $ 9.63 Million, with a yearly change of -19.31%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA9.63 Million | -25.65% |
| 2025 | ILA12.95 Million | -11.24% |
| 2024 | ILA14.59 Million | -12.37% |
| 2023 | ILA16.65 Million | -37.83% |
| 2022 | ILA26.79 Million | -46.11% |
| 2021 | ILA49.70 Million | -32.68% |
| 2020 | ILA73.83 Million | +50.08% |
| 2019 | ILA49.20 Million | -51.72% |
| 2018 | ILA101.90 Million | -18.92% |
| 2017 | ILA125.68 Million | +40.29% |
| 2016 | ILA89.59 Million | -26.13% |
| 2015 | ILA121.28 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Clal Biotechnology Industries Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.63 Million USD |
| MoneyControl | $9.63 Million USD |
| MarketWatch | $9.63 Million USD |
| marketcap.company | $9.63 Million USD |
| Reuters | $9.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Clal Biotechnology Industries Ltd
Clal Biotechnology Industries Ltd. is a private equity and venture capital firm specializing in development stage, pre-clinical; incubation, seed, start-up, early venture, emerging growth, mid venture, late venture, PIPEs, and growth capital stages of financing. It prefers to invest in life sciences, medical devices, biopharmaceutical technologies, and biotechnology companies. The firm seeks to i… Read more